journal
https://read.qxmd.com/read/38695173/deficiency-of-the-deubiquitinase-uchl1-attenuates-pulmonary-arterial-hypertension
#1
JOURNAL ARTICLE
Haiyang Tang, Akash Gupta, Seth A Morrisroe, Changlei Bao, Tae-Hwi Schwantes-An, Geetanjali Gupta, Shuxin Liang, Yanan Sun, Aiai Chu, Ang Luo, Venkateswaran Ramamoorthi Elangovan, Shreya Sangam, Yinan Shi, Samisubbu R Naidu, Jia-Rong Jheng, Sultan Ciftci-Yilmaz, Noel A Warfel, Louise Hecker, Sumegha Mitra, Anna W Coleman, Katie A Lutz, Michael W Pauciulo, Yen-Chun Lai, Ali Javaheri, Rohan Dharmakumar, Wen-Hui Wu, Daniel P Flaherty, Jason H Karnes, Sandra Breuils-Bonnet, Olivier Boucherat, Sebastien Bonnet, Jason X-J Yuan, Jeffrey R Jacobson, Julio D Duarte, William C Nichols, Joe G N Garcia, Ankit A Desai
BACKGROUND: The ubiquitin-proteasome system regulates protein degradation and the development of pulmonary arterial hypertension (PAH), but knowledge about the role of deubiquitinating enzymes in this process is limited. UCHL1 (ubiquitin carboxyl-terminal hydrolase 1), a deubiquitinase, has been shown to reduce AKT1 (AKT serine/threonine kinase 1) degradation, resulting in higher levels. Given that AKT1 is pathological in pulmonary hypertension, we hypothesized that UCHL1 deficiency attenuates PAH development by means of reductions in AKT1...
May 2, 2024: Circulation
https://read.qxmd.com/read/38690659/ertugliflozin-for-functional-mitral-regurgitation-associated-with-heart-failure-effort-trial
#2
JOURNAL ARTICLE
Duk-Hyun Kang, Sung-Ji Park, Sung-Hee Shin, In-Chang Hwang, Yeonyee Elizabeth Yoon, Hyung-Kwan Kim, Mijin Kim, Min-Seok Kim, Sung-Cheol Yun, Jong-Min Song, Seok-Min Kang
BACKGROUND: The morbidity and mortality rates of patients with heart failure (HF) and functional mitral regurgitation (MR) remain substantial despite guideline-directed medical therapy for HF. We evaluated the efficacy of ertugliflozin for reduction of functional MR associated with HF with mild to moderately reduced ejection fraction. METHODS: The EFFORT trial (Ertugliflozin for Functional Mitral Regurgitation) was a multicenter, double-blind, randomized trial to examine the hypothesis that the sodium-glucose cotransporter 2 inhibitor ertugliflozin is effective for improving MR in patients with HF with New York Heart Association functional class II or III, 35%≤ejection fraction<50%, and effective regurgitant orifice area of chronic functional MR >0...
May 1, 2024: Circulation
https://read.qxmd.com/read/38686562/rectifying-mettl4-mediated-n-6-methyladenine-excess-in-mitochondrial-dna-alleviates-heart-failure
#3
JOURNAL ARTICLE
Fuyang Zhang, Ling Zhang, Guangyu Hu, Xiyao Chen, Hui Liu, Congye Li, Xiong Guo, Chong Huang, Fangfang Sun, Tongzheng Li, Zhe Cui, Yongzhen Guo, Wenjun Yan, Yunlong Xia, Zhiyuan Liu, Zhen Lin, Weixun Duan, Linhe Lu, Xinyi Wang, Zhengyang Wang, Shan Wang, Ling Tao
BACKGROUND: Myocardial mitochondrial dysfunction underpins the pathogenesis of heart failure (HF), yet therapeutic options to restore myocardial mitochondrial function are scarce. Epigenetic modifications of mitochondrial DNA (mtDNA), such as methylation, play a pivotal role in modulating mitochondrial homeostasis. However, their involvement in HF remains unclear. METHODS: Experimental HF models were established through continuous angiotensin II and phenylephrine (AngII/PE) infusion or prolonged myocardial ischemia/reperfusion injury...
April 30, 2024: Circulation
https://read.qxmd.com/read/38686559/atherosclerosis-is-a-smooth-muscle-cell-driven-tumor-like-disease
#4
JOURNAL ARTICLE
Huize Pan, Sebastian E Ho, Chenyi Xue, Jian Cui, Quinian S Johanson, Nadja Sachs, Leila S Ross, Fang Li, Robert A Solomon, E Sander Connolly, Virendra I Patel, Lars Maegdefessel, Hanrui Zhang, Muredach P Reilly
BACKGROUND: Atherosclerosis, a leading cause of cardiovascular disease, involves the pathological activation of various cell types, including immunocytes (eg, macrophages and T cells), smooth muscle cells (SMCs), and endothelial cells. Accumulating evidence suggests that transition of SMCs to other cell types, known as phenotypic switching, plays a central role in atherosclerosis development and complications. However, the characteristics of SMC-derived cells and the underlying mechanisms of SMC transition in disease pathogenesis remain poorly understood...
April 30, 2024: Circulation
https://read.qxmd.com/read/38682338/abcg2-expressing-clonal-repopulating-endothelial-cells-serve-to-form-and-maintain-blood-vessels
#5
JOURNAL ARTICLE
Yang Lin, Chang-Hyun Gil, Kimihiko Banno, Masataka Yokoyama, Matthew Wingo, Ellen Go, Nutan Prasain, Ying Liu, Takashi Hato, Hisamichi Naito, Taku Wakabayashi, Musia Sominskaia, Meng Gao, Kevin Chen, Fuqiang Geng, Jesus Maria Gomez Salinero, Sisi Chen, W Christopher Shelley, Momoko Yoshimoto, Sergio Li Calzi, Michael P Murphy, Kyoji Horie, Maria B Grant, Ryan Schreiner, David Redmond, David P Basile, Shahin Rafii, Mervin C Yoder
BACKGROUND: Most organs are maintained lifelong by resident stem/progenitor cells. During development and regeneration, lineage-specific stem/progenitor cells can contribute to the growth or maintenance of different organs, whereas fully differentiated mature cells have less regenerative potential. However, it is unclear whether vascular endothelial cells (ECs) are also replenished by stem/progenitor cells with EC-repopulating potential residing in blood vessels. It has been reported recently that some EC populations possess higher clonal proliferative potential and vessel-forming capacity compared with mature ECs...
April 29, 2024: Circulation
https://read.qxmd.com/read/38682330/cavin1-mediated-herg-dynamics-a-novel-mechanism-underlying-the-interindividual-variability-in-drug-induced-long-qt
#6
JOURNAL ARTICLE
Zeina R Al Sayed, Céline Pereira, Rémi Le Borgne, Christine Viaris de Lesegno, Charlène Jouve, Esthel Pénard, Adeline Mallet, Nihar Masurkar, Gildas Loussouarn, Jean-Marc Verbavatz, Christophe Lamaze, David-Alexandre Trégouët, Jean-Sébastien Hulot
BACKGROUND: Drug-induced QT prolongation (diLQT) is a feared side effect that could expose susceptible individuals to fatal arrhythmias. The occurrence of diLQT is primarily attributed to unintended drug interactions with cardiac ion channels, notably the hERG (human ether-a-go-go-related gene) channels that generate the delayed-rectifier potassium current (IKr ) and thereby regulate the late repolarization phase. There is an important interindividual susceptibility to develop diLQT, which is of unknown origin but can be reproduced in patient-specific induced pluripotent stem cell-derived cardiomyocytes (iPS-CMs)...
April 29, 2024: Circulation
https://read.qxmd.com/read/38682326/pdz-binding-kinase-a-novel-regulator-of-vascular-remodeling-in-pulmonary-arterial-hypertension
#7
JOURNAL ARTICLE
Zsuzsanna Bordan, Robert Batori, Stephen Haigh, Xueyi Li, Mary Louise Meadows, Zach L Brown, Madison A West, Kunzhe Dong, Weihong Han, Yunchao Su, Qian Ma, Yuqing Huo, Jiliang Zhou, Mahmoud Abdelbary, Jennifer Sullivan, Neal L Weintraub, David W Stepp, Feng Chen, Scott A Barman, David J R Fulton
BACKGROUND: Pulmonary arterial hypertension (PAH) is high blood pressure in the lungs that originates from structural changes in small resistance arteries. A defining feature of PAH is the inappropriate remodeling of pulmonary arteries (PA) leading to right ventricle failure and death. Although treatment of PAH has improved, the long-term prognosis for patients remains poor, and more effective targets are needed. METHODS: Gene expression was analyzed by microarray, RNA sequencing, quantitative polymerase chain reaction, Western blotting, and immunostaining of lung and isolated PA in multiple mouse and rat models of pulmonary hypertension (PH) and human PAH...
April 29, 2024: Circulation
https://read.qxmd.com/read/38666382/regeneration-of-nonhuman-primate-hearts-with-human-induced-pluripotent-stem-cell-derived-cardiac-spheroids
#8
JOURNAL ARTICLE
Hideki Kobayashi, Shugo Tohyama, Hajime Ichimura, Noburo Ohashi, Shuji Chino, Yusuke Soma, Hidenori Tani, Yuki Tanaka, Xiao Yang, Naoko Shiba, Shin Kadota, Kotaro Haga, Taijun Moriwaki, Yuika Morita-Umei, Tomohiko C Umei, Otoya Sekine, Yoshikazu Kishino, Hideaki Kanazawa, Hiroyuki Kawagishi, Mitsuhiko Yamada, Kazumasa Narita, Takafumi Naito, Tatsuichiro Seto, Koichiro Kuwahara, Yuji Shiba, Keiichi Fukuda
BACKGROUND: The clinical application of human induced pluripotent stem cell-derived cardiomyocytes (CMs) for cardiac repair commenced with the epicardial delivery of engineered cardiac tissue; however, the feasibility of the direct delivery of human induced pluripotent stem cell-derived CMs into the cardiac muscle layer, which has reportedly induced electrical integration, is unclear because of concerns about poor engraftment of CMs and posttransplant arrhythmias. Thus, in this study, we prepared purified human induced pluripotent stem cell-derived cardiac spheroids (hiPSC-CSs) and investigated whether their direct injection could regenerate infarcted nonhuman primate hearts...
April 26, 2024: Circulation
https://read.qxmd.com/read/38660793/comparison-of-incidence-and-prognostic-impact-of-ischemic-major-bleeding-and-heart-failure-events-in-patients-with-chronic-coronary-syndrome-insights-from-the-coronor-registry
#9
JOURNAL ARTICLE
Gilles Lemesle, Nicolas Lamblin, Guillaume Schurtz, Julien Labreuche, Alain Duhamel, Basile Verdier, Philippe Gabriel Steg, Christophe Bauters
BACKGROUND: Evaluation of the residual risk in patient with chronic coronary syndrome is challenging in daily practice. Several types of events (myocardial infarction, ischemic stroke, bleeding, and heart failure [HF]) may occur, and their impact on subsequent mortality is unclear in the era of modern evidence-based pharmacotherapy. METHODS: CORONOR (Suivi d'une cohorte de patients Coronariens stables en région Nord-pas-de-Calais) is a prospective multicenter cohort that enrolled 4184 consecutive unselected outpatients with chronic coronary syndrome...
April 25, 2024: Circulation
https://read.qxmd.com/read/38660790/the-tricuspid-valve-a-review-of-pathology-imaging-and-current-treatment-options-a-scientific-statement-from-the-american-heart-association
#10
REVIEW
Laura J Davidson, Gilbert H L Tang, Edwin C Ho, Marat Fudim, Tiberio Frisoli, Anton Camaj, Margaret T Bowers, Sofia Carolina Masri, Pavan Atluri, Joanna Chikwe, Peter J Mason, Jason C Kovacic, George D Dangas
Tricuspid valve disease is an often underrecognized clinical problem that is associated with significant morbidity and mortality. Unfortunately, patients will often present late in their disease course with severe right-sided heart failure, pulmonary hypertension, and life-limiting symptoms that have few durable treatment options. Traditionally, the only treatment for tricuspid valve disease has been medical therapy or surgery; however, there have been increasing interest and success with the use of transcatheter tricuspid valve therapies over the past several years to treat patients with previously limited therapeutic options...
April 25, 2024: Circulation
https://read.qxmd.com/read/38660786/sptlc3-is-essential-for-complex-i-activity-and-contributes-to-ischemic-cardiomyopathy
#11
JOURNAL ARTICLE
Anna Kovilakath, Adolfo G Mauro, Yolander Valentine, Frank Raucci, Maryam Jamil, Christiane Carter, Jeremy Thompson, Qun Chen, Beutner Gisela, Yang Yue, Jeremy Allegood, Xiaoxin X Wang, Jordan Dail, Teja Devarakonda, Komuraiah Myakala, Jolene J Windle, Mark A Subler, David Montefusco, Belinda Willard, Ali Javaheri, Tytus Bernas, Sushil K Mahata, Moshe Levi, Jinze Liu, George A Porter, Edward J Lesnefsky, Fadi N Salloum, L Ashley Cowart
BACKGROUND: Dysregulated metabolism of bioactive sphingolipids, including ceramides and sphingosine-1-phosphate, has been implicated in cardiovascular disease, although the specific species, disease contexts, and cellular roles are not completely understood. Sphingolipids are produced by the serine palmitoyltransferase enzyme, canonically composed of 2 subunits, SPTLC1 (serine palmitoyltransferase long chain base subunit 1) and SPTLC2 (serine palmitoyltransferase long chain base subunit 2)...
April 25, 2024: Circulation
https://read.qxmd.com/read/38634276/diagnosis-and-management-of-cardiac-sarcoidosis-a-scientific-statement-from-the-american-heart-association
#12
REVIEW
Richard K Cheng, Michelle M Kittleson, Craig J Beavers, David H Birnie, Ron Blankstein, Paco E Bravo, Nisha A Gilotra, Marc A Judson, Kristen K Patton, Leonie Rose-Bovino
Cardiac sarcoidosis is an infiltrative cardiomyopathy that results from granulomatous inflammation of the myocardium and may present with high-grade conduction disease, ventricular arrhythmias, and right or left ventricular dysfunction. Over the past several decades, the prevalence of cardiac sarcoidosis has increased. Definitive histological confirmation is often not possible, so clinicians frequently face uncertainty about the accuracy of diagnosis. Hence, the likelihood of cardiac sarcoidosis should be thought of as a continuum (definite, highly probable, probable, possible, low probability, unlikely) rather than in a binary fashion...
April 18, 2024: Circulation
https://read.qxmd.com/read/38623761/systolic-blood-pressure-and-survival-to-very-old-age-results-from-the-women-s-health-initiative
#13
JOURNAL ARTICLE
Bernhard Haring, Chris A Andrews, Kathleen Hovey, Aladdin H Shadyab, Andrea LaCroix, Lisa Warsinger Martin, Milagros C Rosal, Lewis H Kuller, Elena Salmoirago-Blotcher, Nazmus Saquib, Patrick Koo, Deepika Laddu, Marcia L Stefanick, JoAnn E Manson, Sylvia Wassertheil-Smoller, Michael J LaMonte
BACKGROUND: The relationship between systolic blood pressure (SBP) and longevity is not fully understood. We aimed to determine which SBP levels in women ≥65 years of age with or without blood pressure medication were associated with the highest probability of surviving to 90 years of age. METHODS: The study population consisted of 16570 participants enrolled in the Women's Health Initiative who were eligible to survive to 90 years of age by February 28, 2020, without a history of cardiovascular disease, diabetes, or cancer...
April 16, 2024: Circulation
https://read.qxmd.com/read/38618723/environmental-exposures-and-pediatric-cardiology-a-scientific-statement-from-the-american-heart-association
#14
REVIEW
Justin P Zachariah, Pei-Ni Jone, Andrew O Agbaje, Heather H Ryan, Leonardo Trasande, Wei Perng, Shohreh F Farzan
Environmental toxicants and pollutants are causes of adverse health consequences, including well-established associations between environmental exposures and cardiovascular diseases. Environmental degradation is widely prevalent and has a long latency period between exposure and health outcome, potentially placing a large number of individuals at risk of these health consequences. Emerging evidence suggests that environmental exposures in early life may be key risk factors for cardiovascular conditions across the life span...
April 15, 2024: Circulation
https://read.qxmd.com/read/38606558/positive-vasoreactivity-testing-in-pulmonary-arterial-hypertension-therapeutic-consequences-treatment-patterns-and-outcomes-in-the-modern-management-era
#15
JOURNAL ARTICLE
Felix Gerhardt, Eva Fiessler, Karen M Olsson, Moritz Z Kayser, Gabor Kovacs, Henning Gall, H Ardeschir Ghofrani, Roza Badr Eslam, Irene M Lang, Nicola Benjamin, Ekkehard Grünig, Michael Halank, Tobias J Lange, Silvia Ulrich, Hanno Leuchte, Matthias Held, Hans Klose, Ralf Ewert, Heinrike Wilkens, Carmen Pizarro, Dirk Skowasch, Max Wissmüller, Martin Hellmich, Horst Olschewski, Marius M Hoeper, Stephan Rosenkranz
BACKGROUND: Among patients with pulmonary arterial hypertension (PAH), acute vasoreactivity testing during right heart catheterization may identify acute vasoresponders, for whom treatment with high-dose calcium channel blockers (CCBs) is recommended. However, long-term outcomes in the current era remain largely unknown. We sought to evaluate the implications of acute vasoreactivity response for long-term response to CCBs and other outcomes. METHODS: Patients diagnosed with PAH between January 1999 and December 2018 at 15 pulmonary hypertension centers were included and analyzed retrospectively...
April 12, 2024: Circulation
https://read.qxmd.com/read/38602110/patient-centered-adult-cardiovascular-care-a-scientific-statement-from-the-american-heart-association
#16
REVIEW
Michael J Goldfarb, Martha Abshire Saylor, Biykem Bozkurt, Jillianne Code, Katherine E Di Palo, Angela Durante, Kristin Flanary, Ruth Masterson Creber, Modele O Ogunniyi, Fatima Rodriguez, Martha Gulati
Patient-centered care is gaining widespread acceptance by the medical and lay communities and is increasingly recognized as a goal of high-quality health care delivery. Patient-centered care is based on ethical principles and aims at establishing a partnership between the health care team and patient, family member, or both in the care planning and decision-making process. Patient-centered care involves providing respectful care by tailoring management decisions to patients' beliefs, preferences, and values...
April 11, 2024: Circulation
https://read.qxmd.com/read/38597097/quality-of-life-in-patients-with-chronic-limb-threatening-ischemia-treated-with-revascularization
#17
JOURNAL ARTICLE
Matthew T Menard, Alik Farber, Richard J Powell, Kenneth Rosenfield, Michael S Conte, Taye H Hamza, John A Kaufman, Mark J Cziraky, Mark A Creager, Michael D Dake, Michael R Jaff, Diane Reid, George Sopko, Christopher J White, Michael B Strong, Max van Over, Emiliano Chisci, Philip P Goodney, Bruce Gray, Ahmed Kayssi, Jeffrey J Siracuse, Niteesh K Choudhry
BACKGROUND: In the BEST-CLI trial (Best Endovascular Versus Best Surgical Therapy for Patients With Chronic Limb-Threatening Ischemia), a prespecified secondary objective was to assess the effects of revascularization strategy on health-related quality of life (HRQoL). METHODS: Patients with chronic limb-threatening ischemia were randomized to surgical bypass (Bypass) or endovascular intervention (Endo) in 2 parallel trials. Cohort 1 included patients with single-segment great saphenous vein; cohort 2 included those lacking suitable single-segment great saphenous vein...
April 10, 2024: Circulation
https://read.qxmd.com/read/38594972/a-prospective-randomized-trial-of-direct-oral-anticoagulant-therapy-with-a-fully-magnetically-levitated-lvad-the-dot-hm3-study
#18
LETTER
Ivan Netuka, Zuzana Tucanova, Peter Ivak, Stanislav Gregor, Dushan Michael Kolesar, Tomas Marek, Vojtech Melenovsky, Jana Binova, Zora Dorazilova, Marketa Hegarova, Martina Podolec, Hynek Riha, Jean M Connors, Mandeep R Mehra
No abstract text is available yet for this article.
April 9, 2024: Circulation
https://read.qxmd.com/read/38587557/effect-of-alcohol-mediated-renal-denervation-on-blood-pressure-in-the-presence-of-antihypertensive-medications-primary-results-from-the-target-bp-i-randomized-clinical-trial
#19
JOURNAL ARTICLE
David E Kandzari, Michael A Weber, Atul Pathak, James P Zidar, Manish Saxena, Shukri W David, Roland E Schmieder, Adam J Janas, Christoph Langer, Alexandre Persu, Farrell O Mendelsohn, Koen Ameloot, Malcolm Foster Iii, Tim A Fischell, Helen Parise, Felix Mahfoud
BACKGROUND: Renal denervation (RDN) has demonstrated clinically relevant reductions in blood pressure among individuals with uncontrolled hypertension despite lifestyle intervention and medications. The safety and effectiveness of alcohol-mediated RDN has not been formally studied in this indication. METHODS: TARGET BP I is a prospective, international, sham-controlled, randomized, patient- and assessor-blinded trial investigating the safety and efficacy of alcohol-mediated RDN...
April 8, 2024: Circulation
https://read.qxmd.com/read/38587333/topical-versus-intravenous-tranexamic-acid-in-patients-undergoing-cardiac-surgery-the-deposition-randomized-controlled-trial
#20
JOURNAL ARTICLE
André Lamy, Dmitry A Sirota, Frederic Jacques, Ahmad Poostizadeh, Nicolas Noiseux, Sergey Efremov, Philippe Demers, Boris Akselrod, Chew Yin Wang, Rakesh C Arora, Piotr Branny, Shay P McGuinness, Craig D Brown, Hugues Jeanmart, Qiang Zhao, Haibo Zhang, Emilie P Belley-Côté, Richard P Whitlock, Austin Browne, Ingrid Copland, Jessica Vincent, Rutaba Khatun, Kumar Balasubramanian, Shrikant I Bangdiwala, Michael H McGillion, Alison E Fox-Robichaud, Jessica Spence, Salim Yusuf, P J Devereaux
BACKGROUND: Although intravenous tranexamic acid is used in cardiac surgery to reduce bleeding and transfusion, topical tranexamic acid results in lower plasma concentrations compared to intravenous tranexamic acid, which may lower the risk of seizures. We aimed to determine whether topical tranexamic acid reduces the risk of in-hospital seizure without increasing the risk of transfusion among cardiac surgery patients. METHODS: We conducted a multicenter, double dummy, blinded, randomized controlled trial of patients recruited by convenience sampling in academic hospitals undergoing cardiac surgery with cardiopulmonary bypass...
April 8, 2024: Circulation
journal
journal
20069
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.